Balchem Corp. 10-Q Summary: Quarter Ended March 31, 2000
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2000. Balchem Corporation develops, manufactures, and markets specialty performance ingredients for food, feed, and medical sterilization industries. Operations are divided into two segments: Specialty Products (repackaging specialty gases) and Encapsulated Products (micro-encapsulation of ingredients).
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Net Sales | $7,751,000 | $7,047,000 |
| Gross Margin | $3,113,000 (40.2%) | $2,840,000 (40.3%) |
| Net Earnings | $809,000 | $750,000 |
| Diluted EPS | $0.17 | $0.15 |
| Operating Cash Flow | $1,590,000 | $1,647,000 |
| Total Debt (Current + Long-term) | $750,000 | $2,750,000 |
| Cash and Equivalents | $1,941,000 | $1,689,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% year-over-year. The Encapsulated Products segment drove this with a 21% increase, while Specialty Products grew 5%.
- Expense Increases: Operating expenses rose 11% to $1.819 million, primarily due to increased advertising and payroll for sales personnel supporting the animal nutrition business.
- Debt Reduction: Total debt decreased significantly by $2.0 million (from $2.75 million to $750,000), resulting in a shift from net interest expense of $43,000 in 1999 to net interest income of $2,000 in 2000.
- Segment Performance: The Specialty Products segment generated $1.41 million in profit. The Encapsulated Products segment reported a loss of $116,000, an increase from the prior year's $92,000 loss, attributed to higher marketing costs.
Outlook, Risks, and Management Commentary
- Product Launch: Commercial sales of "Reashure," an encapsulated choline for ruminant animals, are beginning to favorably impact the Encapsulated Products segment. Additional sales staff have been hired to support this growth.
- Capital Expenditures: CapEx for the quarter was $352,000. Management projects total CapEx for calendar year 2000 to be approximately $840,000.
- Share Repurchase: The company has repurchased 157,816 shares under a 1999 authorization, with 1,000,000 shares authorized total. Repurchases depend on cash flow and market conditions.
- Liquidity: The company maintains a $2,000,000 line of credit with no outstanding borrowings as of March 31, 2000. Management states no current demands will materially affect liquidity.
- Market Risk: Interest rate risk is considered not material. A 100 basis point increase would increase annual interest expense by approximately $8,000. There is no material exposure to foreign currency or commodity price risk.
Investor Verification Checklist
- Verify the sustainability of the 21% revenue growth in the Encapsulated Products segment driven by the new Reashure product.
- Monitor the Encapsulated Products segment's path to profitability given the increased operating loss despite revenue growth.
- Confirm the utilization of the $2,000,000 credit line remains zero as projected.
- Track the execution of the remaining share repurchase authorization (approx. 842,000 shares remaining).
- Review the impact of the new accounting standard (FAS 133) on derivatives when it becomes effective in fiscal years beginning after June 15, 2000.